You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百奧賽圖(02315.HK)RenMab技術平臺再獲日本專利授權
百奧賽圖-B(02315.HK)公佈,其自主研發的全人抗體小鼠RenMab平臺關鍵技術獲得由日本專利局(Japan Patent Office, JPO)頒發的發明專利證書。 RenMab小鼠是百奧賽圖自主研發的RenMice全人抗體發現平臺家族的核心成員之一。百奧賽圖利用獨有的超大片段染色體工程技術,將小鼠的抗體重鏈和輕鏈可變區基因原位全區段替換爲人的相應基因。基於RenMice平臺的「千鼠萬抗」工程,針對上千潛在藥物靶點產生上百萬條全人抗體分子,以及高潛力臨牀前候選抗體分子,截至2024年底百奧賽圖已達成近200個抗體分子的授權或轉讓合作。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account